The US Food and Drug Administration has cleared the Clarify Medical Phototherapy System for marketing, and the new smart, at-home UVB phototherapy system will be available to patients with chronic skin diseases in November.
Clarify’s proprietary technology allows patients with psoriasis, vitiligo and eczema to receive UVB phototherapy in their homes, linked to their physicians and to Clarify support services through their smartphones.
Clarify has begun meeting with existing and prospective shareholders in preparation for a Series A Financing. The company is raising $10 million to support product launch in November. It expects to close the offering in near future.